Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2024-07-23 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
董事长、监事会主席、职工代表监及高级管理人员换届公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the company's chairman, supervisory board chairman, employee representative supervisor, and senior management personnel. It details the election and appointment of these individuals, their qualifications, and the impact of these changes on the company. There is no financial data, no mention of financial results, no audit information, or any other report type content. The document is clearly about management changes and appointments, which fits the category of Board/Management Information (MANG). The document length is 2523 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2024-07-23 Chinese
关于对外投资设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's external investment to establish a wholly-owned subsidiary. It details the investment amount, purpose, risk assessment, and board approval. It does not contain financial statements or detailed financial performance data. The document is a formal announcement of a capital investment activity, specifically the establishment of a subsidiary, which relates to capital structure changes. It is not a full financial report, audit, or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS.
2024-07-23 Chinese
2024年第一次职工代表大会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's employee representative meeting, detailing the election of a new employee representative supervisor to the supervisory board. It includes meeting details, voting results, and compliance statements. There is no financial data, no mention of annual or interim reports, no audit information, no earnings data, and no regulatory filings or legal proceedings. The document is an official announcement of a board/management related decision, specifically about the supervisory board composition. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2024-07-23 Chinese
第五届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the fifth supervisory board of Yunnan Biovalley Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results for the election of the supervisory board chairman. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory filings beyond the meeting resolution. The content fits the category of Board/Management Information as it announces changes in the supervisory board leadership and meeting resolutions.
2024-07-23 Chinese
广东广和律师事务所关于云南生物谷药业股份有限公司 2024年第一次临时股东大会之法律意见书
Regulatory Filings
2024-07-23 Chinese
关于对北京证券交易所问询函的回复
Regulatory Filings
2024-07-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.